Figure 1: Asthma-related measures for the ICS cohorts during the baseline year and the year after step-down in ICS dose to a once-daily regimen (A) or a twice-daily regimen (B). All measures improved significantly between baseline and post step-down (p<0.001) with the exception of the composite database measure of no loss of asthma control plus limited SABA use, which was comparable in the QD cohort and fell significantly (p<0.001) in the BD cohort.
Goto home»